News and research before you hear about it on CNBC and others. Claim your one week free trial for StreetInsider Premium here.
Tilray Medical Launches Sleep-Focused CBN Overnight Oil for Medical Cannabis Patients in Canada
Tilray Brands, Inc. (“Tilray” or the “Company”) (Nasdaq: TLRY; TSX: TLRY), a leading global cannabis and consumer packaged goods company, inspiring and empowering the global community to live your best life, today announced that its medical cannabis brand, Aphria, has launched CBN Night Oil, the brand’s first medical CBN oil product formulated for nighttime use by patients.
Blair MacNeil, President of Tilray Canada, said, “Tilray Medical is committed to providing patients in Canada and around the world with safe, high-quality cannabinoid medicines. We are excited to add a dedicated nighttime oil to Aphria’s medical portfolio and expand our offering of effective medical cannabis products to patients with a wider range of needs. »
CBN, or cannabinol, is derived from THC and is known to help improve sleep duration and quality.1 Aphria’s CBN-dominant oil is carefully formulated with 30mg of CBN per ml and 10mg of THC per ml (in a 50ml bottle) and is made from broad-spectrum cannabis distillate. Designed to be used in conjunction with a nightly routine, Aphria’s CBN Night Oil is now available across Canada at www.TilrayMedical.ca
About Tilray Medical
Tilray Medical is dedicated to transforming lives and fostering the dignity of patients in need through safe and trusted access to a global portfolio of medical cannabis brands, including Tilray, Aphria, Broken Coast and Symbios. Tilray went from being one of the first companies to become a licensed producer of medical cannabis in Canada to building the first GMP-certified cannabis production facilities in Europe, first in Portugal and then in Germany. Today, Tilray Medical is one of the largest branded suppliers of medical cannabis to patients, doctors, hospitals, pharmacies, researchers and governments, in 20 countries and on five continents.
About Tilray Brands
Tilray Brands, Inc. (Nasdaq: TLRY and TSX: TLRY) is a leading global cannabis and consumer packaged goods company with operations in Canada, United States, Europe, Australia and in Latin America and that changes people’s lives for the better. – one person at a time – inspiring and empowering the global community to live their best life by providing them with products that meet the needs of their mind, body and soul and invoke a sense of well- be. Tilray’s mission is to be the trusted partner of its patients and consumers by providing them with a cultured experience, health and well-being through differentiated, high-quality brands and innovative products. A pioneer in cannabis research, cultivation and distribution, Tilray’s unparalleled production platform supports more than 20 brands in over 20 countries, including complete cannabis offerings, hemp edibles and alcoholic beverages.
For more information on how we are opening up a world of wellness, visit www.Tilray.com.
Certain statements contained in this communication that are not historical facts constitute forward-looking information or forward-looking statements (collectively, “forward-looking statements”) under Canadian securities laws and within the meaning of Section 27A of the Securities Act of 1933, as amended. , and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be subject to the “safe harbor” created by those sections and other applicable laws. Forward-looking statements can be identified by words such as “anticipate”, “future”, “should”, “could”, “allow”, “potential”, “envisage”, “believe”, “anticipate”, “estimate, “”plan”, “expect”, “intend”, “may”, “project”, “will”, “would” and the negative form of these terms or similar expressions, although not all forward-looking statements contain such identifying words. Certain material factors, estimates, objectives, projections or assumptions were used in drawing the conclusions contained in the forward-looking statements throughout this communication. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analysis or current expectations regarding, among other things, the Company’s ability to bring new and innovative products to market worldwide. could cause actual results, performance or achievements to differ materially from any forward-looking statements, and other risks and uncertainties not currently known to the Company or that the Company deems immaterial could also cause actual results or events to differ materially from those those expressed in the forward-looking statements contained herein. For a more detailed discussion of these risks and other factors, see Tilray’s most recently filed annual information sheet and Tilray’s annual report on Form 10-K (and other periodic reports filed with the SEC) of Tilray written with the SEC and available on EDGAR. The forward-looking statements included in this communication are made as of the date of this communication, and the Company undertakes no obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise, except as required by securities laws. applicable securities so require. .
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/6056552f-5a26-4b91-a644-f5ce8055f330
1Walsh JH, Maddison KJ, Rankin T, Murray K, McArdle N, Ree MJ, Hillman DR, Eastwood PR. Treating symptoms of insomnia with medicinal cannabis: a randomized crossover trial of the effectiveness of a cannabinoid drug versus a placebo. Sleep. 2021 Nov 12;44(11):zsab149. Doi: 10.1093/sleep/zsab149. PMID: 34115851; PMCID: PMC8598183.
Karniol IG, Shirakawa I, Takahashi RN, Knobel E, Musty RE. Effects of delta9-tetrahydrocannabinol and cannabinol in humans. Pharmacology. 1975;13(6):502-12. doi: 10.1159/000136944. PMID: 1221432.
The post Tilray Brands, Inc. (TLRY) Launches Sleep-Focused CBN Night Oil appeared first on Marijuana Stocks | Cannabis investments and news. Roots of a budding industry.(TM).